Medical Advocates
Doravirine (MK-1439)

Main Page

ARV Investigational Drugs

Main New/Noteworthy

Home Page

Last Update: November 25, 2016
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

November 2016

An Evaluation of Doravirine Pharmacokinetics When Switching From Efavirenz to Doravirine in Healthy Subjects.
Yee KL, Sanchez RI, Auger P, et al Antimicrob Agents Chemother. 2016 Nov 21

Journal Abstracts , Papers, and Commentaries

An Evaluation of Doravirine Pharmacokinetics When Switching From Efavirenz to Doravirine in Healthy Subjects.
Yee KL, Sanchez RI, Auger P,
Antimicrob Agents Chemother. 2016 Nov 21
Abstract

A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.
Anderson MS, Khalilieh S, Yee KL
Clin Pharmacokinet. 2016 Oct 4.
Abstract

Rilpivirine and Doravirine have complementary efficacies against NNRTI-Resistant HIV-1 mutants.
Smith SJ, Pauly GT, Akram A,
J Acquir Immune Defic Syndr. 2016 Apr 23
Abstract
Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.
Feng M, Sachs NA, Xu M, et al Antimicrob Agents Chemother. 2016 Mar 25;60(4):2241-7.
A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naïve HIV-infected patients.
Schürmann D, Sobotha C, Gilmartin J, et al
AIDS. 2015 Sep 13
Abstract

Highly Efficient Synthesis of HIV NNRTI Doravirine.
Gauthier DR Jr, Sherry BD, Cao Y, et al
Org Lett. 2015 Mar 9.
Abstract
FULL-TEXT ARTICLE
In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.
Feng M, Wang D, Grobler JA, ET AL
Antimicrob Agents Chemother. 2015 Jan;59(1):590-8.
Paper
A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals.
Schürmann D, Sobotha C, Gilmartin J, et al
AIDS. 2016 Jan 2;30(1):57-63.
Abstract
Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS, Gilmartin J, Cilissen C, et al
Antivir Ther. 2014 Dec 3.
Abstract
FULL-TEXT ARTICLE
Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients.
Gatell JM, Morales-Ramirez JO, Hagins DP,
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19532.
Paper
FULL-TEXT ARTICLE
In Vitro Characterization of MK-1439: A Novel HIV-1 Non-Nucleoside Reverse transcriptase Inhibitor.
Lai MT, Feng M, Falgueyret JP, et al
Antimicrob Agents Chemother. 2013 Dec 30
Paper
Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of
resistant mutant HIV viruses.
Côté B, Burch JD, Asante-Appiah E,et al
Bioorg Med Chem Lett. 2013 Dec 24
Abstract

ARV Investigational Drugs

Main New/Noteworthy

Home Page

Doravirine (MK-1439)